Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
1.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer.

Clinical breast cancer·2026
Same author

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB-IIIA non-small cell lung cancer.

Translational lung cancer research·2026
Same author

A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer.

Investigational new drugs·2026

Related Experiment Video

Updated: Mar 28, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Propelling Immunotherapy Combinations Into the Clinic.

Nishan Tchekmedyian, Jhanelle E Gray, Benjamin C Creelan

    Oncology (Williston Park, N.Y.)
    |December 19, 2015
    PubMed
    Summary

    Immune checkpoint inhibitors offer long-term survival for some advanced cancers. Combining therapies can enhance T-cell responses against tumors by improving T-cell generation, trafficking, and function.

    More Related Videos

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
    09:15

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

    Published on: February 24, 2023

    4.2K
    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
    10:18

    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

    Published on: July 7, 2023

    1.8K

    Related Experiment Videos

    Last Updated: Mar 28, 2026

    Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
    12:42

    Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

    Published on: January 7, 2019

    10.4K
    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
    09:15

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

    Published on: February 24, 2023

    4.2K
    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
    10:18

    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

    Published on: July 7, 2023

    1.8K

    Area of Science:

    • Immunology
    • Oncology
    • Cancer Research

    Background:

    • Immune checkpoint inhibitors (ICIs) provide durable survival in advanced melanoma and lung cancer.
    • Enhancing T-cell antitumor responses is crucial for improving patient outcomes.

    Purpose of the Study:

    • To explore strategies for harnessing the immune system to improve T-cell antitumor responses.
    • To identify promising combination therapies involving ICIs.

    Main Methods:

    • Review of current research on T-cell antitumor response elements (generation, trafficking, function).
    • Analysis of combination strategies with ICIs, including dual blockade, costimulatory agonists, innate immunity enhancers, and other novel agents.

    Main Results:

    • Successful T-cell response requires generation, trafficking, and effector function within the tumor microenvironment.
    • Promising strategies include dual ICI blockade and combinations with agonists, innate immunity enhancers, IDO inhibitors, adoptive T-cell transfer, vaccines, small molecules, and radiation therapy.

    Conclusions:

    • Novel clinical trials are investigating combinations of targeted agents and ICIs.
    • The goal is to achieve deeper and more durable antitumor responses in a broader patient population.